Compare Stocks: ZFGN, MNPR, DRUG, and CTMX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.36 +0.3%	$3.37	$1.77 ▼ $8.21	$729.96M	2.12	2.60 million shs	1.43 million shs
DRUG Bright Minds Biosciences	$76.44 -2.0%	$70.69	$38.00 ▼ $123.75	$759.11M	-5.27	191,720 shs	151,386 shs
MNPR Monopar Therapeutics	$113.04 +2.4%	$96.11	$29.18 ▼ $124.82	$739.65M	1.47	299,532 shs	165,720 shs
ZFGN Zafgen	$5.09 +1.0%	$18.47	$0.62 ▼ $2.76	$190.72M	0.27	360,199 shs	1.32 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+0.30%	-2.89%	-8.70%	-6.93%	+89.83%
DRUG Bright Minds Biosciences	-2.00%	-3.64%	+0.68%	-1.33%	+88.55%
MNPR Monopar Therapeutics	+2.38%	-5.18%	+4.00%	+90.72%	+237.33%
ZFGN Zafgen	0.00%	0.00%	0.00%	0.00%	+37.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.36 +0.3%	$3.37	$1.77 ▼ $8.21	$729.96M	2.12	2.60 million shs	1.43 million shs
DRUG Bright Minds Biosciences	$76.44 -2.0%	$70.69	$38.00 ▼ $123.75	$759.11M	-5.27	191,720 shs	151,386 shs
MNPR Monopar Therapeutics	$113.04 +2.4%	$96.11	$29.18 ▼ $124.82	$739.65M	1.47	299,532 shs	165,720 shs
ZFGN Zafgen	$5.09 +1.0%	$18.47	$0.62 ▼ $2.76	$190.72M	0.27	360,199 shs	1.32 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+0.30%	-2.89%	-8.70%	-6.93%	+89.83%
DRUG Bright Minds Biosciences	-2.00%	-3.64%	+0.68%	-1.33%	+88.55%
MNPR Monopar Therapeutics	+2.38%	-5.18%	+4.00%	+90.72%	+237.33%
ZFGN Zafgen	0.00%	0.00%	0.00%	0.00%	+37.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$11.90	254.17% Upside
DRUG Bright Minds Biosciences	3.14	Buy	$143.83	88.17% Upside
MNPR Monopar Therapeutics	2.86	Moderate Buy	$117.42	3.87% Upside
ZFGN Zafgen	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZFGN, MNPR, DRUG, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$125.00 ➝ $128.00
8/13/2026	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$109.00 ➝ $119.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/13/2026	MNPR Monopar Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	MNPR Monopar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$117.00 ➝ $133.00
8/10/2026	CTMX CytomX Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
7/23/2026	MNPR Monopar Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$125.00
7/22/2026	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$105.00 ➝ $125.00
7/21/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/21/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	MNPR Monopar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$76.20M	9.61	N/A	N/A	$1.39 per share	2.42
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$19.50 per share	N/A
ZFGN Zafgen	N/A	N/A	N/A	N/A	$1.35 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	N/A
DRUG Bright Minds Biosciences	-$8.74M	-$2.44	N/A	N/A	N/A	N/A	-20.58%	-20.25%	N/A
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	N/A
ZFGN Zafgen	-$45.41M	-$1.07	N/A	N/A	N/A	N/A	-51.34%	-34.55%	N/A

Latest ZFGN, MNPR, DRUG, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2831	-$0.17	+$1.1131	-$0.17	N/A	N/A
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
5/20/2026	Q2 2026	DRUG Bright Minds Biosciences	-$0.8633	-$0.80	+$0.0633	-$0.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
ZFGN Zafgen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
DRUG Bright Minds Biosciences	N/A	81.47	81.47
MNPR Monopar Therapeutics	N/A	33.56	56.04
ZFGN Zafgen	0.26	6.56	6.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
DRUG Bright Minds Biosciences	40.52%
MNPR Monopar Therapeutics	1.83%
ZFGN Zafgen	70.43%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
DRUG Bright Minds Biosciences	42.66%
MNPR Monopar Therapeutics	9.70%
ZFGN Zafgen	14.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	217.90 million	209.62 million	Optionable
DRUG Bright Minds Biosciences	N/A	9.73 million	5.58 million	Not Optionable
MNPR Monopar Therapeutics	10	6.70 million	6.05 million	Not Optionable
ZFGN Zafgen	38	37.47 million	N/A	Not Optionable

ZFGN, MNPR, DRUG, and CTMX Headlines

Recent News About These Companies

GSK/Sirtris compounds dogged by assay artifacts

May 21, 2024 | nature.comN

Tokyo Steel Manufacturing Co Ltd 5423

May 16, 2024 | morningstar.comM

Diagnosing Diabetes: Not So Simple

November 2, 2023 | medscape.comM

Do New Weight Loss Meds Mean the End of Bariatric Surgery?

October 6, 2023 | medscape.comM

Prader-Willi syndrome

August 23, 2023 | pharmaphorum.comP

The Omnipod 5 System: Trial Results From ENDO 2021

August 4, 2023 | medscape.comM

Beta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?

July 5, 2023 | medscape.comM

Oral Semaglutide Brings GLP-1s to Primary Care

May 20, 2023 | medscape.comM

Clinical Trials - Different Phases of the trial News, Research and Latest Updates

May 20, 2023 | medindia.netM

Obesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital Journal

May 12, 2023 | news.google.comN

Weight Loss and Obesity Management Market Insights With ... - Taiwan News

May 11, 2023 | news.google.comN

Global Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern Examiner

May 4, 2023 | news.google.comN

Weight Loss and Obesity Management Market May See a Big Move ... - Digital Journal

May 2, 2023 | news.google.comN

Ironwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best Stocks

May 2, 2023 | news.google.comN

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation

April 29, 2023 | medscape.comM

Fast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape Reference

April 21, 2023 | news.google.comN

Anti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital Journal

April 20, 2023 | news.google.comN

Anti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPR

April 14, 2023 | news.google.comN

New ADA Standards: Promoting Health

April 13, 2023 | medscape.comM

New ADA Standards: Promoting Health

April 13, 2023 | medscape.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZFGN, MNPR, DRUG, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$3.36 +0.01 (+0.30%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.40 +0.04 (+1.07%)

As of 08/14/2026 07:56 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Bright Minds Biosciences NASDAQ:DRUG

$76.44 -1.56 (-2.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.25 -0.19 (-0.25%)

As of 08/14/2026 07:34 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Monopar Therapeutics NASDAQ:MNPR

$113.04 +2.63 (+2.38%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$112.93 -0.11 (-0.10%)

As of 08/14/2026 07:34 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Zafgen NASDAQ:ZFGN

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZFGN, MNPR, DRUG, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZFGN, MNPR, DRUG, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZFGN, MNPR, DRUG, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZFGN, MNPR, DRUG, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Bright Minds Biosciences NASDAQ:DRUG

Monopar Therapeutics NASDAQ:MNPR

Zafgen NASDAQ:ZFGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZFGN, MNPR, DRUG, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZFGN, MNPR, DRUG, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZFGN, MNPR, DRUG, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZFGN, MNPR, DRUG, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Bright Minds Biosciences NASDAQ:DRUG

Monopar Therapeutics NASDAQ:MNPR

Zafgen NASDAQ:ZFGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools